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enter cells. These macrophage-tropic viruses are termed R5
viruses. This co-receptor pattern explains why persons who
are homozygous for a 32 base pair deletion in CCR5
(CCR5)32) are relatively resistant to the usual R5 strains.'
After infection there is a rapid rise in plasma viraemia with
widespread dissemination of the virus to many organs
including the lymphoid system and central nervous system.
VIROLOGICAL EVENTS AT PRIMARY INFECTION
Primary infection is usually accompanied by high titres of
virus, often to levels in excess of 1 million HIV-l RNA
copies/mI of plasma.' The plasma viraemia is curtailed by
the emergence of the immune response predominantly
mediated by CD8+ cytotoxic Iymphocytes. It has been
shown that as many as 1 in 17 CD8+ T cells in the
peripheral blood may be cytotoxic T-Iymphocytes
specifically targeted against the virus (these may be
reported on a blood count as atypical reactive Iymphocytes,
which are also noted in glandular fever caused by Epstein-
Barr virus infections'). The diagnosis of acute primary
infection will rely on the detection of HIV-RNA by
polymerase chain reaction (PCR) or by a positive p24
antigen test in a subject who tests negative for HIV
antibodies. Treatment of acute primary HIV infection (if
identified) is recommended for a number of reasons: (I) to
limit the dissemination of the virus; [if) to establish a lower
setpoint; and [iil) to preserve crucial HIV-specific immune
responses, which have been shown to be lost early in
infection. The du ration of treatment of primary infection is
currently uncertain but it should be of the order 9 - 12
months (the normal maturation period for the immune
response being approximately 6 months). Thereafter
treatment is deferred until the virological or immunological
endpoints, according to the guidelines, are reached.
As can be seen in Fig. 1, the immune response is effective
in reducing the viral levels to a level that is termed the
virological serpoinr. This setpoint varies between
individuals and is influenceo by a number of factors
including the quality of the immune response, geneIic
factors and antiretroviral therapy. The level of the setpoint





A greater understanding of the dynamics of HIV-l infection
has resulted from the development and application of
molecular biology technologies, in particular the nucleic
acid technologies for the detection and quantification of
virus in various tissue compartments. This has led to a
greater appreciation of the interaction between the virus
and the immune system and the immunopathogenesis of
the disease. Based on these factors, the development of
treatment guidelines has become a more rational process.
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It has been shown that persons with acute HIV infection
demonstrate selective infection with certain variants of
HIV-l. Sexually transmitted variants are typically
macrophage-tropic, which are taken up by susceptible cells
bearing the CCR5 receptor. This chemokine receptor acts as
a co-receptor which is a necessary requirement for HIV to
Fig. 7. Dynamics ofHIV-I.
EARLY EVENTS IN HIV-l INFECTION
The most common mode of HIV-l infection is sexual
transmission across the genital mucosa.' Studies in the
simian animal model have provided important insights into
this process.' The first cellular targets of the virus are
Langerhans cells, which are tissue dendritic cells found in
the lamina propria in the cervicovaginal epithelium. Within
2 days after infection virus can be detected in the draining
internal iliac lymph nodes; thereafter dissemination of the
virus occurs and virus can be cultured from the peripheral
blood 5 days after infection. In the human there appears
to be a variation in the time from initial infection to
viraemia, with estimates varying from 4 to 11 days.' Clearly,
breaks in the epithelium associated with trauma or genital
infections will accelerate this process.
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Fig. 2. Viral decay
the intrinsic decay rates in the various cellular and
extracellular compartments that harbour virus.
Subsequent research" showed that the initial rapid decay
was the result of clearance of free virions from the plasma
and the loss of the productively infected cells.
Studies have shown that after the initial rapid decay in the
first' - 2 weeks of treatment, plasma virus declined at a
slower rate, reflecting the turnover of a longer-lived cell
population or reservoir." This reservoir accounts for only a
small proportion of the total virus production in an
untreated individual and becomes evident only when the
cells that produce most of the plasma virus have decayed.
The half-life of the cells responsible for this second-phase
decay is estimated to be , - 4 weeks. In many patients the
second-phase decay brings the levels of virus down below
the level of detection in currently available assays « 50
copies/ml plasmal. It is assumed that provided there are no
hitherto undiscovered additional reservoirs, the second-
phase of decay extrapolates to zero residual cells after 2 -
3 years of completely suppressive therapy. The nature of
the compartments contributing to this second-phase decay
is thought to be tissue macrophages and dendritic cells.
It has been shown that if therapy is withdrawn in patients,
who have been on long-term suppressive therapy, a
vigorous viral rebound occurs 10 - 12 days after stopping
therapy. This implies that there is a viral compartment in
existence that in the first instance must be extremely
stable, and secondly is not influenced by the antiretroviral
therapy that has effectively eliminated virus from the
compartments mentioned previously. It is thought that
long-lived memory cells (CD45+RO+) bearing integrated
provirus constitute this long-lived reservoir." This form of
latent infection constitutes an extreme barrier to the
eradication of HIV, as research has shown that the
frequency of these latently infected cells has shown no
detectable decrease during the first 2years of therapy." The
VIRAL DECAY ON TREATMENT
patients with a low(er) setpoint.' One important
observation to emerge from measurements of plasma virus
levels in HIV-, infection is that viral replication continues
throughout the disease even in the clinically latent
asymptomatic phase. In untreated, asymptomatic patients
the plasma HIV-, RNA levels are typically in the range of
10' - la' copies/ml of plasma. TItres of infectious
culturable virus are several orders of magnitude lower,
indicating tha much of this plasma virus is defective,
decayed or neutralised' This steady state is reasonably
stable and is a reflection that virus production equals viral
clearance. Current evidence favours the idea that most of
the plasma virus comes from recently infected CD4+
Iymphocytes in the peripheral lymphoid tissues. It is to be
remembered that only 2'1'0 of the Iymphocyte population
circulates at any given time. The majority of viral
replication takes place in the lymph nodes and other
lymphoid tissue such as the mucosa and skin-associated
lymphoid tissue'
Between 93010 and 99010 of the daily turnover of virus
results from the productively infected Iymphocytes (Fig. 1).
Up to 109 virus particles are produced and cleared on adaily
basis; this is accompanied by an increased daily turnover of
CD4 cells. It has been estimated" that the average half-life
of the plasma virus is short, probably less than 6 hours. The
source of the remaining , - 7010 of daily viral turnover is
derived from tissue sources including macrophages,
dendritic cells and to a lesser degree, the release of trapped
virus and activation of latently infected cells. It has been
shown that infection of resting memory CD4+ cells (post
integration latency) results in a small but nonetheless
important reservoir of infection. The Iifespan of these cells
is long and because of their resting state currently available
antiretroviral drugs, which rely on attacking relevant
enzymes while the virus is replicating, are thus rendered
ineffective. Strategies to purge these cells of the integrated
latent virus are currently under investigation, because until
this reservoir is eliminated the cure of HIV infection will
remain elusive.
FIRST-PHASE DECAY
Research in 1995 describing the effects of potent
antiretroviral therapy in HIV-infected individuals not only
changed the course of therapy but provided novel insights
into the pathogenesis of the disease,,·n The critical finding
was that potent antiretroviral drugs produced a rapid
exponential drop in plasma virus. Typically plasma virus
levels dropped by lOO-fold in a period of 2 weeks (Fig. 2).
This rapid exponential decline observed in treated patients
was taken as evidence that, as the drugs prevent any new
infection of susceptible cells, the observed decreases reflect
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decay rates of this reservoir are extremely slow, consistent
with the long-term survival of resting memory cells (mean
intermitotic interval 5.5 months").
TURNOVER OF CD4+ LYMPHOCYTES
A hallmark of HIV-l disease is the loss of C04+
Iymphocytes (Table I). The rate of loss of these cells varies
between 20 and 80 cells per year but will vary according to
the factors such as viral load, with increased loss of cells
occurring in patients with higher viral loads. Up to 10' cells
are destroyed and replenished in a quasi-steady state in
early disease. A variety of mechanisms contribute to the
loss of C04+ cells, including direct effects of the virus and
indirect immunological effects. Recent research has
implicated a failure of regenerative thymopoesis as an
important mechanism, resulting both from infection of
stem-cell precursors and failure of programming of na'ive T
cells in the thymus or thymic equivalents.'" There is an
impressive increase in both CD4+ and CD8+ Iymphocytes
following the institution of antiretroviral therapy. The early
rise in Iymphocytes is due to cells bearing the memory
phenotype (CD45RO+) and comes about as a result of the
redistribution of these cells from peripheral lymphoid
tissues. There follows a more gradual increase over months
of cells bearing the naIve phenotype [C0454RA+) as part of
the immune reconstitution process.
TABLE I. CD4 LYMPHOCYTE DEPLETION
• Hallmark of HIV disease
• 2 billion CD4 cells destroyed each day
• C04 destruction by many means
• Failure of homeostasis related to regenerative capacity
• Role of the thymus
VIRAL DIVERSITY AND RESISTANCE
The high rate of viral replication of HIV-1 promotes the
development of different but related strains within the
blood and lymphoid tissues of the patient. This
heterogeneity of viral strains leads to a 'quasispecies' of
viral strains within individual patients, which broadens as
the infection progresses over time. The factors associated
with viral variability are listed in Table 11.
The replication dynamics in various anatomical
compartments differ leading to the generation of distinct
quasispecies within the central nervous system, genital
tract and other tissue sites. As the penetration of drugs in
these sites varies, the generation of distinct resistant
TABLE 11. VARIABIUTY OF HIV
• RNA viruses lack proof-reading mechanism
• High replicative rate
• RT enzyme is error prone
• Selection pressure
• Recombination events
leads to the generation of viral 'quasispecies'
species within these sites may occur. There is always the
possibility that viruses possessing resistant patterns,
distinct from the populations within the blood, can traffic
back into the blood.
It is also important to understand that avirus that has such
a high replicative capacity can generate mutations
associated with resistance prior to the introduction of
specific antiretroviral drugs. It has been estimated that
there is a mutation rate of one nucleotide base per
replication cycle. Against a background HIV replication rate
of 10' viral particles per day, this leads to the generation of
every possible mutation 10' per day." Single mutations
associated with drug resistance are therefore likely to exist
in the untreated patient. The replicative capacity of these
variants is often impaired (viral 'fitness' is reduced) and
they exist in the quasispecies as a minority population, but
have the capability to become a major population when a
specific drug is introduced.
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